As filed with the Securities and Exchange Commission on March 19, 2025
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
Under
The Securities Act of 1933
GALECTO, INC.
(Exact name of registrant as specified in its charter)
|
|
|
Delaware |
|
37-1957007 |
(State or other jurisdiction of incorporation or organization) |
|
(I.R.S. Employer Identification Number) |
75 State Street, Suite 100
Boston, Massachusetts, 02109
Ole Maaloes Vej 3
DK-2200 Copenhagen N
Denmark
(+45) 70 70 52 10
(Address of Principal Executive Offices)
Galecto, Inc. 2020 Equity Incentive Plan
(Full Title of the Plans)
The Corporation Trust Company
c/o Galecto, Inc.
1209 Orange Street
Wilmington, DC 19801
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
William Hicks, Esq.
Daniel Bagliebter, Esq.
Nishant Dharia, Esq.
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
One Financial Center
Boston, MA 02111
(617) 542-6000
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
Large accelerated filer |
|
☐ |
|
Accelerated filer |
|
☐ |
|
|
|
|
|||
Non-accelerated filer |
|
☒ |
|
Smaller reporting company |
|
☒ |
|
|
|
|
|||
|
|
|
|
Emerging growth company |
|
☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
EXPLANATORY NOTE
This Registration Statement on Form S-8 registers 65,849 additional shares of common stock, $0.00001 par value per share, of Galecto, Inc. (the “Registrant”), under the Registrant’s 2020 Equity Incentive Plan (the “2020 Plan”), representing an automatic increase of 65,849 shares reserved under the 2020 Plan effective January 1, 2025 pursuant to the provisions of the 2020 Plan. This registration statement registers additional securities of the same class as other securities for which registration statements filed on Form S-8 on November 4, 2020 (File No. 333-249852), March 29, 2021 (File No. 333-254805), March 9, 2023 (File No. 333-270380) and March 8, 2024 (File No. 333-277792) relating to an employee benefit plan are effective (collectively, the “Prior Registration Statements”). The information contained in the Prior Registration Statements is hereby incorporated by reference pursuant to General Instruction E of Form S-8.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 8. |
Exhibits. |
EXHIBIT INDEX
|
|
|
Exhibit No. |
|
Description |
4.1 |
|
|
|
|
|
4.2 |
|
|
|
|
|
4.3 |
|
|
|
|
|
4.4 |
|
|
|
|
|
4.5 |
|
|
|
|
|
5.1* |
|
Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. |
|
|
|
23.1* |
|
Consent of EY Godkendt Revisionspartnerselskab, Independent Registered Public Accounting Firm. |
|
|
|
23.2* |
|
Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in Exhibit 5.1). |
|
|
|
24.1* |
|
Power of Attorney (included on signature page to this registration statement). |
|
|
|
99.1+ |
|
|
|
|
|
107* |
|
+ |
Denotes management contract or compensatory plan or arrangement. |
* |
Filed herewith. |
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Copenhagen, Denmark, on the 19th day of March, 2025.
|
|
Galecto, Inc. |
|
Date: March 19, 2025 |
|
By: |
/s/ Hans T. Schambye, M.D., Ph.D. |
|
|
|
Hans T. Schambye, M.D., Ph.D. |
|
|
|
Chief Executive Officer and President |
POWER OF ATTORNEY
KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints Hans T. Schambye and Lori Firmani, and each of them, either of whom may act without the joinder of the other, as his or her true and lawful attorneys-in-fact and agents with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the date indicated below.
|
|
|
|
|
Name |
|
Title |
|
Date |
|
|
|
||
/s/ Hans T. Schambye, M.D., Ph.D. Hans T. Schambye, M.D., Ph.D. |
|
President, Chief Executive Officer and Director (Principal Executive Officer) |
|
March 19, 2025 |
|
|
|
||
/s/ Lori Firmani Lori Firmani |
|
Interim Chief Financial Officer (Principal Financial Officer and Accounting Officer) |
|
March 19, 2025 |
|
|
|
||
/s/ Carl Goldfischer, M.D Carl Goldfischer, M.D. |
|
Chairman |
|
March 19, 2025 |
|
|
|
||
/s/ Jayson Dallas, M.D. |
|
Director |
|
March 19, 2025 |
Jayson Dallas, M.D. |
|
|
|
|
|
|
|
|
|
/s/ Amit D. Munshi Amit D. Munshi |
|
Director |
|
March 19, 2025 |
|
|
|
||
/s/ Anne Prener, M.D., Ph.D. Anne Prener, M.D., Ph.D. |
|
Director |
|
March 19, 2025 |
|
|
|
||
/s/ David Shapiro, M.D. David Shapiro, M.D. |
|
Director |
|
March 19, 2025 |
|
|
|
||
/s/ Amy Wechsler, M.D. Amy Wechsler, M.D. |
|
Director |
|
March 19, 2025 |